Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413153 · ClinicalTrials.gov registry record · NA
Metabolic Effects of Switching Kaletra to Boosted Reyataz
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT00413153: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00413153 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00413153, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
To study the effects of switching from Kaletra to Boosted Reyataz on glucose, lipids and fat in HIV-infected patients.
Interventions
- DRUG atazanavir/ritonavir
- DRUG lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413153
The ClinicalTrials.gov registry entry for NCT00413153 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which atazanavir/ritonavir is the first listed.
NCT00413153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413153 about?
NCT00413153 is a clinical study titled "Metabolic Effects of Switching Kaletra to Boosted Reyataz". To study the effects of switching from Kaletra to Boosted Reyataz on glucose, lipids and fat in HIV-infected patients.
What is the current status of trial NCT00413153?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2006-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00413153?
The interventions under investigation include: atazanavir/ritonavir (DRUG), lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00413153?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.